Updates in Upper GI Cancers From ASCO and ASCO GI 2024 - Episode 6

Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

EP. 2: 4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

EP. 3: A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

EP. 4: Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

EP. 5: Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

Now Viewing

EP. 6: Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers